Literature DB >> 8760745

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.

L J Walsh1, C A Wong, M Pringle, A E Tattersfield.   

Abstract

OBJECTIVE: To determine the prevalence of continuous use of oral steroids in the general population, the conditions for which they are prescribed, and the extent to which patients taking oral steroids are taking treatment to prevent osteoporosis.
DESIGN: A cross sectional study with a four year retrospective review of drug treatment.
SETTING: Eight large general practices in central and southern Nottinghamshire.
SUBJECTS: A population of 65,786 patients (52% women) registered with a general practitioner during 1995.
RESULTS: 303 patients (65% (197) women) aged 12-94 years were currently taking "continuous" (for at least three months) oral corticosteroid treatment. This figure represents 0.5% of the total population and 1.4% (245/17 114) of patients aged 55 years or more (1.7% (166/9601) of women). The usual steroid was prednisolone (97% (294/303)), the mean dose was 8.0 mg/day, and the median duration of oral steroid treatment determined in 149 patients was three years. The most common conditions for which continuous oral steroids were prescribed were rheumatoid arthritis (23% (70)), polymyalgia rheumatica (22% (66)), and asthma or chronic obstructive airways disease (19% (59)). Only 41 (14%) of the 303 patients taking oral steroids had received treatment for the prevention of osteoporosis over the past four years. Although 37 of the 41 patients were women, only 10% (18/181) of the women over 45 years taking continuous oral corticosteroids were currently taking hormone replacement therapy.
CONCLUSIONS: If our figures are typical then they suggest that over 250,000 people in the United Kingdom are taking continuous oral steroids and that most of these are taking no prophylaxis against osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760745      PMCID: PMC2351752          DOI: 10.1136/bmj.313.7053.344

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  22 in total

1.  Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study.

Authors:  M Luengo; C Picado; L Del Rio; N Guañabens; J M Montserrat; J Setoain
Journal:  Am Rev Respir Dis       Date:  1990-07

Review 2.  Pathogenesis and treatment of steroid osteoporosis.

Authors:  I R Reid
Journal:  Clin Endocrinol (Oxf)       Date:  1989-01       Impact factor: 3.478

Review 3.  Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors:  B P Lukert; L G Raisz
Journal:  Ann Intern Med       Date:  1990-03-01       Impact factor: 25.391

4.  Department of Health shoots itself in the hip. Why the report of the Advisory Group on Osteoporosis undermines evidence based purchasing.

Authors:  T A Sheldon; A Raffle; I Watt
Journal:  BMJ       Date:  1996-02-03

5.  Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids.

Authors:  A Verstraeten; J Dequeker
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

6.  Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss.

Authors:  B P Lukert; B E Johnson; R G Robinson
Journal:  J Bone Miner Res       Date:  1992-09       Impact factor: 6.741

7.  Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

Authors:  M Luengo; C Picado; L Del Rio; N Guañabens; J M Montserrat; J Setoain
Journal:  Thorax       Date:  1991-11       Impact factor: 9.139

8.  Steroid-induced fractures and bone loss in patients with asthma.

Authors:  A D Adinoff; J R Hollister
Journal:  N Engl J Med       Date:  1983-08-04       Impact factor: 91.245

9.  Association of cytomegalovirus infection with autoimmune type 1 diabetes.

Authors:  C Y Pak; H M Eun; R G McArthur; J W Yoon
Journal:  Lancet       Date:  1988-07-02       Impact factor: 79.321

10.  Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors:  I R Reid; A R King; C J Alexander; H K Ibbertson
Journal:  Lancet       Date:  1988-01-23       Impact factor: 79.321

View more
  72 in total

Review 1.  Bone loss and glucocorticoid therapy in patients with respiratory disease.

Authors:  A Fairney
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Low use of long-term hormone replacement therapy in Denmark.

Authors:  C Olesen; F H Steffensen; H T Sørensen; G L Nielsen; J Olsen; U Bergman
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

3.  Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review.

Authors:  S Sauerland; M Nagelschmidt; P Mallmann; E A Neugebauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

4.  Steroids cause osteoporosis.

Authors:  S Paget
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

5.  Prevention of corticosteroid induced osteoporosis.

Authors:  P Lips
Journal:  BMJ       Date:  1999-05-22

6.  Management of bone disease in patients on long term glucocorticoid therapy.

Authors:  J E Compston
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

7.  Poncirin prevents bone loss in glucocorticoid-induced osteoporosis in vivo and in vitro.

Authors:  Hyung-Young Yoon; Ye-Yeon Won; Yoon-Sok Chung
Journal:  J Bone Miner Metab       Date:  2012-03-13       Impact factor: 2.626

Review 8.  Bone turnover markers: use in osteoporosis.

Authors:  Kim Naylor; Richard Eastell
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

Review 9.  Prevention and treatment of bone changes associated with exposure to glucocorticoids.

Authors:  Amy H Warriner; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

10.  Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.

Authors:  I A Campbell; J G Douglas; R M Francis; R J Prescott; D M Reid
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.